Clinical trials: Bacteria
Oral Bacteria
Investigate Oral Bacteria in Adult Population
To compare the antimicrobial efficacy of three dentifrices on oral bacteria
- Trial name
- NCT00762177
- Testing
- Fluoride, Fluoride, Triclosan, Stannous Fluoride
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Colgate Palmolive
Oral Bacteria, Halitosis
Effect of a Probiotic Water on Oral Health in Adults
The purpose of this study is to evaluate the effects of consuming a probiotic on salivary, plaque, and tongue bacteria, as well as oral malodor (bad breath).
- Trial name
- NCT04473404
- Testing
- Streptococcus salivarius DB-B5 - 2 billion CFU/day, Streptococcus salivarius DB-B5 - 10 billion CFU/day
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Dose Biosystems Inc.
Type 2 Diabetes, Healthy
Human Faecal Microbiota in Type 2 Diabetes
The main objective of the clinical trial is to investigate whether overweight type 2 diabetic patients have a different fecal microbiota profile compared with age, gender, BMI matched subjects and with lean healthy subjects…
- Conditions
- Type 2 Diabetes, Healthy, Overweight
- Trial name
- NCT02694172
- Testing
- Fiber rich cereal bars
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Société des Produits Nestlé (SPN)
Pneumonia
Safety, Tolerability and Pharmacokinetics of Aerosolized Amikacin in Intubated and Mechanically-ventilated Patients With Nosocomial Pneumonia
This study is to understand how the inhaled form of amikacin is spread throughout the human body and how it is eliminated from the body and to make sure that giving an inhaled form of Amikacin to patients is safe and well…
- Trial name
- NCT01021436
- Testing
- Amikacin inhalation solution (BAY41-6551)
- Where
- 6 sites in United States, France
- Volunteers
- 30 people
- Sponsor
- Bayer
Gingivitis
Dose Finding Study to Assess Octenidine Mouthwash Concentrations in Comparison to Placebo
The objective of this clinical trial is to identify the most efficacious octenidine dihydrochloride concentration regarding bacterial count reduction in comparison to a placebo in the oral cavity.
- Trial name
- OML0113 (NCT02138552)
- Testing
- Octenidine dihydrochloride
- Where
- 2 sites in Germany
- Volunteers
- 90 people
- Sponsor
- Schülke & Mayr GmbH
Pneumonia, Pneumococcal, Community Acquired Infections
New Antibiotic to Treat Patients With Community-acquired Pneumonia Due to a Specific Bacteria (S. Pneumoniae Pneumonia)
This study will treat patients who have a community-acquired pneumonia that is due to a specific bacteria (S. pneumoniae)
- Conditions
- Pneumonia, Pneumococcal, Community Acquired Infections, Gram-positive Bacterial Infections
- Trial name
- NCT00035269
- Testing
- Antibiotic
- Where
- 46 sites in United States, Slovakia and 2 more
- Volunteers
- 230 people
- Sponsor
- Pfizer
Chronic Obstructive Pulmonary Disease
An Efficacy Study of BCS Clearing the Oral Colonized Bacterium in Hospitalized Patients With COPD
The purpose of study is to evaluate the efficacy and safety of Benzalkonium Chloride Solution clearing the oral colonized bacterium in hospitalized patients with COPD.
- Trial name
- NCT02269800
- Testing
- Benzalkonium chloride solution, Normal saline
- Volunteers
- 60 people
- Sponsor
- Lustre Pharmaceutical Lab Co., Ltd
Intestinal Bacteria Flora Disturbance
Multi-Antibiotic Resistance Carriage in Gut Flora
Prevalence Study evaluating the acquisition of carriage of multidrug-resistant Gram-negative bacteria (MDRGNB) in the gut flora in volunteers of French Armed Forces staying from 4 to 6 months outside France.
- Trial name
- MARC (NCT01591538)
- Where
- France
- Volunteers
- 272 people, healthy volunteers welcome
- Sponsor
- Da Volterra
Oral Health
Effect of an Oral Probiotic Tablet on Oral Bacteria and Clinical Measurements (ProBiora3)
The purpose of this study is to determine if an oral probiotic tablet taken once a day for twelve weeks can decrease the numbers of bacteria that are associated with tooth decay and gum disease in a dentally healthy, young adult…
- Trial name
- NCT01520974
- Testing
- ProBiora3 mints
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Oragenics, Inc.
Bloodstream Infection, Sepsis
Clinical Performance Study of Microbio InfectID-BSI for Detection of Bacteria and Yeast With Patient Blood Samples
The objective of the study is to determine the efficacy of the Microbio InfectID-BSI qPCR kit in a clinical laboratory environment using patient whole blood for pathogen detection and identification versus standard of care…
- Conditions
- Bloodstream Infection, Sepsis, Septic Shock
- Trial name
- IID-BSIqPCR (NCT06531031)
- Testing
- InfectID-BSI (Bloodstream Infection) qPCR Assay
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 1,500 people
- Sponsor
- Microbio Co Ltd
Resistant to Gram-positive, Gram-negative and Anaerobic Bacteria
To Evaluate the Pharmacokinetics and Safety of TQD3606 for Injection in Subjects With Renal Insufficiency
The study is an open, parallel, single-dose phase I clinical study to evaluate the pharmacokinetics and safety of TQD3606 for injection in subjects with renal insufficiency.
- Trial name
- NCT06672276
- Testing
- TQD3606
- Where
- 2 sites in China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Pneumonia
A Study to Determine the Correct Dose of Amikacin Which is Delivered Directly to the Lungs of Ventilated Patients as an Aerosol Via an Investigational Device Called the Pulmonary Delivery Device System (PDDS)
This study is part of a research program too see if amikacin delivered as an aerosol directly to the lungs in combination with IV antibiotic therapy can help intubated patients with gram-negative pneumonia get better faster than…
- Trial name
- NCT01004445
- Testing
- Amikacin (BAY41-6551)
- Where
- 20 sites in United States, France and 1 more
- Volunteers
- 69 people
- Sponsor
- Bayer
Skin and Subcutaneous Tissue Bacterial Infections, Skin Structures and Soft Tissue Infections
Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections
The purpose of this study is to evaluate the effects of Delafloxacin versus Vancomycin plus Aztreonam in the treatment of patients with acute bacterial skin and soft tissue infections.
- Trial name
- NCT01984684
- Testing
- delafloxacin, vancomycin, aztreonam
- Where
- 94 sites in United States, Argentina and 14 more
- Volunteers
- 850 people
- Sponsor
- Melinta Therapeutics, Inc.
Skin and Subcutaneous Tissue Bacterial Infections
Delafloxacin Versus Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections
This study was designed to evaluate the efficacy of delafloxacin patients with acute bacterial skin and soft tissue infections (ABSSSI).
- Trial name
- NCT01811732
- Testing
- Delafloxacin, Vancomycin, Aztreonam
- Where
- 50 sites in United States, Croatia and 5 more
- Volunteers
- 660 people
- Sponsor
- Melinta Therapeutics, Inc.
Acne Vulgaris
Acne Vulgaris Related Microbiology and Serology
This will be an investigation to determine the quality of the serological immune responses against Propionibacterium acnes (P. acnes) in acne patients compared to healthy individuals.
- Trial name
- NCT04056598
- Testing
- Study of humoral immunity
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Sanofi
Acute Otitis Media
Study to Identify and Characterize Bacteria Causing Acute Otitis Media in South African Children
The purpose of this study is to identify and characterize the bacteria causing acute otitis media episode in HIV-positive and HIV-negative children (>=3 months to <5 years) in South Africa.
- Trial name
- NCT01031082
- Testing
- Middle ear fluid, nasopharyngeal aspirate and urine sample.
- Where
- South Africa
- Volunteers
- 265 people
- Sponsor
- GlaxoSmithKline
Gram-Positive Bacterial Infections, Escherichia Coli Infections
Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units
To determine the value of increasing use of piperacillin/tazobactam as empiric therapy and restricting extended-spectrum cephalosporins in reducing the cases of ESBL producing Escherichia coli and Klebsiella pneumoniae in…
- Conditions
- Gram-Positive Bacterial Infections, Escherichia Coli Infections, Klebsiella Infections
- Trial name
- NCT00167999
- Testing
- piperacillin-tazobactam
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Superficial Skin and Soft Tissue Infections Caused by Gram-positive Bacteria
A Phase I Clinical Trial to Evaluate CMS-F021 Following Single and Multiple Doses in Healthy Participants
"This study is a first-in-human (FIH) trial of CMS-F021 conducted in healthy Chinese adult participants, consisting of two parts: Part 1-a single ascending dose (SAD) study (referred to as Part 1 SAD), and Part 2-a multiple…
- Trial name
- NCT07790770
- Testing
- CMS-F021 Gel, Drug: CMS-F021 Gel healthy participant
- Where
- China
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Dermavon Holdings Limited
Bacterial Vaginosis, Vulvovaginal Candidiasis
Efficacy, Safety, and Dose-response of a Live Biotherapeutic Product in Women With Acute Vaginal Infection
The purpose of this clinical trial is to investigate the clinical efficacy and safety of a Live Biotherapeutic Product (BGY-1601-VT) intended as a first line of treatment in cases of acute vaginal infection without upfront…
- Trial name
- ELINA (NCT06450990)
- Testing
- BGY-1601-VT
- Volunteers
- 165 people
- Sponsor
- NEXBIOME THERAPEUTICS
Cataract Surgery
Study of DE-108 Ophthalmic Solution in Patients Who Are Scheduled for Cataract Surgery
The purpose of this study is to evaluate superior efficacy of DE-108 ophthalmic solution to that of Levofloxacin 0.5% ophthalmic solution as well as safety of the former used for perioperative bacteria eradication in patients who…
- Trial name
- NCT02573610
- Testing
- DE-108, Levofloxacin 0.5%
- Where
- 6 sites in South Korea
- Volunteers
- 576 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.